Kidney Week

Abstract: SA-PO796

Health Care Resource Utilization (HCRU) Burden in C3 Glomerulopathy (C3G) in the United States: A Retrospective Linked Electronic Medical Records (EMR) and Claims Database Analysis

Session Information

• C3G, TMA, MGRS, Amyloidosis, and More
  October 26, 2024 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Glomerular Diseases

• 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

• Ndife, Briana C., Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States

Briana C. Ndife, MPH

• Khairnar, Rahul, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States

Rahul Khairnar, PhD

• Bose, Anirban, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States

Anirban Bose, MD

• Thakkar, Karishma, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States

Karishma Thakkar, PharmD, MS

• Boyd, Marley K., Genesis Research LLC, Hoboken, New Jersey, United States

Marley K. Boyd, MS

• Leiras, Claudia, Genesis Research LLC, Hoboken, New Jersey, United States

Claudia Leiras, MS, PhD

• Shrestha, Swastina, Genesis Research LLC, Hoboken, New Jersey, United States

Swastina Shrestha, MS

• Mariani, Laura H., University of Michigan, Ann Arbor, Michigan, United States

Laura H. Mariani, MD, MS, FASN

Background

C3G is a chronic, rare glomerulonephritis in which pathological deposition of C3 in the glomeruli leads to progressive chronic kidney disease (CKD). This analysis aimed to evaluate C3G-related HCRU in the US.

Methods

We performed a retrospective analysis of patients (pts) diagnosed with C3G (Jan 2017–Sep 2022), with EMRs and linked medical claims in the HealthVerity database. Pts were ≥12 years (y) of age and had records ≥12 months prior to and following first diagnosis (index). Annual, per patient HCRU was assessed by CKD stage (defined as: mild [stage 1–2, reference], moderate [stage 3–4], severe [stage 5]) and proteinuria level (<1, ≥1 g/g) at index. HCRU rate ratios (RRs) for proteinuria groups and CKD stages were estimated using a generalized linear model with log link and negative binomial distribution, with 95% confidence intervals (CIs) and p-values.

Results

At index, the final cohort of 677 pts was majority female (63%), with a mean (standard deviation [SD]) age of 44y (19). Comorbidities included hypertension (55%), type II diabetes (24%), congestive heart failure (11%), atrial fibrillation (4%) and myocardial infarction (3%). Mean estimated glomerular filtration rate (n=152) was 78 (SD 37) mL/min/1.73m² and median proteinuria was 1.5 (n=49, interquartile range 0.3–3.3) g/g. Mean number of total visits was 65.7 (SD 74.8). Proteinuria level ≥1 g/g was associated with a 2-fold increase in total visits versus those with levels <1 g/g (RR 2.08, 95% CI 1.18–3.69, p=0.012). Increasing CKD stage associated with increasing total visits (moderate CKD: RR 1.78, 95% CI 1.42–2.23, p<0.0001; severe CKD: RR 2.68, 95% CI 2.04–3.51, p<0.0001) (Table).

Conclusion

Pts with higher proteinuria and CKD stage have a higher HCRU burden, highlighting the need for therapies that reduce proteinuria and prevent CKD progression.

Funding

• Commercial Support – Novartis Pharmaceutical Corporation